A large peer-reviewed study published in the British Medical Journal on July 22, 2026, has found that adults using GLP-1 receptor agonist drugs — including semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — had a significantly higher rate of clinically recorded hair loss compared with people taking two other commonly prescribed diabetes medications. The U.S. Food and Drug Administration has confirmed it is now formally evaluating this as a safety signal.
The finding matters for the tens of millions of Americans who are currently taking or considering GLP-1 drugs. Hair loss is not listed as a labeled side effect in current U.S. prescribing information for these medications, meaning many patients who have experienced shedding may not have connected it to their prescription.
Why This Matters
When patients experience an unlabeled side effect, two things often happen. They may stop their medication without telling their prescriber, losing the cardiovascular and metabolic benefits that made the drug clinically valuable. Or they may continue the drug without understanding that the shedding is most likely temporary and associated with the rate of weight loss rather than permanent follicle damage. Neither outcome is ideal.
As the BMJ research team wrote: "Although the absolute risk of clinically recorded alopecia associated with GLP-1 receptor agonist use is low, the observed association may still influence patients' satisfaction, adherence, and decisions to start or continue therapy." That sentence is the practical center of this story — a low but real risk that is now documented well enough to guide a conversation between patient and clinician.
What We Know So Far
Researchers at the University of Pennsylvania Health System used electronic health records to conduct what is known as a target trial emulation — a rigorous design that mimics a randomized trial using real-world patient data. They compared rates of clinically recorded alopecia in adults with type 2 diabetes who started GLP-1 receptor agonists against those starting SGLT-2 inhibitors or DPP-4 inhibitors, two other standard diabetes drug classes.
In total, 12,004 patients using GLP-1 drugs were compared with 15,221 using SGLT-2 inhibitors, and a separate group of 11,964 GLP-1 users was compared with 11,233 using DPP-4 inhibitors. Data ran from January 2019 through September 2024. The researchers adjusted for age, sex, ethnicity, pre-existing conditions, other medication use, and body mass index to isolate the association with GLP-1 use.
After adjustment, GLP-1 use was associated with a 37 percent higher risk of hair loss than SGLT-2 inhibitor use and a 68 percent higher risk than DPP-4 inhibitor use. In absolute terms, rates of clinically recorded hair loss were 6.91 per 1,000 person years in GLP-1 users compared with 5.04 per 1,000 person years among SGLT-2 users.
To put the absolute risk in plain terms: roughly 7 out of every 1,000 GLP-1 users per year developed a clinically recorded hair loss diagnosis — compared to roughly 5 out of every 1,000 users of the comparison drug. The relative difference is meaningful. The absolute number of affected people remains low.
What the Evidence Shows — and What It Does Not
The study found an association, not proof of direct drug causation. The research team identified rapid weight loss and reduced caloric intake as the most likely mechanism — specifically, that caloric restriction during significant weight loss can create physiological stress and micronutrient deficiencies in iron, zinc, and biotin, all of which are critical for normal hair growth.
This classification has clinical significance. The hair loss observed in GLP-1 users is driven by the weight loss the drug produces, not by the drug acting directly on hair follicles. That means two things: first, the rate and degree of weight loss may be modifiable to reduce hair shedding; and second, the shedding may be manageable without stopping the medication.
Critically, the analysis found that the elevated risk was specific to non-scarring alopecia. Non-scarring alopecia means the hair follicles remain intact. Hair can regrow once the trigger — in this case, rapid weight loss — stabilizes. This distinguishes it from scarring forms of alopecia where permanent follicle destruction makes regrowth unlikely.
The study has limitations the authors acknowledge. It was observational, meaning other unmeasured factors could have contributed to the results. The researchers also lacked detailed clinical information about the severity, extent, duration, and reversibility of hair loss in individual patients after stopping treatment.
The study type is observational. It enrolled adults with type 2 diabetes, and results may not apply identically to people using GLP-1 drugs solely for weight management without diabetes. Current medical recommendations for GLP-1 drugs have not changed as a result of this study.
What Regulators Are Seeing
The BMJ paper noted that the U.S. Food and Drug Administration's Adverse Event Reporting System has received reports of hair loss following initiation of GLP-1 receptor agonists. "In response," the researchers wrote, "the FDA has indicated that it is evaluating this potential safety signal."
The United Kingdom's Medicines and Healthcare products Regulatory Agency has received 399 reports of hair loss linked specifically to tirzepatide in 2026 alone, following 541 such reports in 2025. For semaglutide, the UK agency received 148 reports in 2026 and 164 in 2025, according to reporting by ITV News. Those figures represent spontaneous regulatory reports from a single country and are not the same as clinical trial data, but they provide context for the scale of the signal being evaluated.
Who Faces the Greatest Risk?
The BMJ study enrolled adults with type 2 diabetes, meaning the specific numbers — 6.91 per 1,000 person years — apply directly to that population. People using GLP-1 drugs for weight management without diabetes may have different risk profiles, though the mechanism is thought to be the same.
People losing weight rapidly, those with existing low levels of iron, ferritin, zinc, or biotin, women in general, and individuals who are starting GLP-1 drugs at higher doses may be more likely to notice hair shedding. The shedding, when it occurs, typically begins two to four months after the most rapid phase of weight loss — a delay that can make it difficult to connect to the medication without being informed.
Symptoms and Warning Signs to Watch For
Hair shedding associated with GLP-1 use typically presents as diffuse thinning across the scalp, most noticeable during washing, brushing, or on pillows and drains. It differs from pattern baldness in that it is distributed across the scalp rather than concentrated at hairlines or crowns. In most reported cases, hair begins to regrow once weight loss stabilizes or the drug dose is reduced.
If hair loss is accompanied by fatigue, cold sensitivity, brittle nails, or irregular menstrual cycles, these symptoms may indicate an underlying thyroid issue or nutritional deficiency that should be evaluated separately. Those conditions can also cause hair loss and are worth ruling out regardless of GLP-1 use.
What You Can Do Now
Patients currently experiencing hair thinning on semaglutide or tirzepatide should raise it with their prescribing clinician at the next appointment. A blood panel checking ferritin, iron, zinc, thyroid function, and in some cases biotin levels is a reasonable starting point. Correcting a deficiency can reduce the severity and duration of shedding.
Clinicians may consider a slower dose escalation schedule to reduce the pace of weight loss for patients who are particularly concerned about hair shedding. Do not stop a prescribed medication because of this side effect without discussing it with a health-care provider, particularly when the drug is also providing diabetes control or cardiovascular protection.
For patients about to begin GLP-1 therapy, this conversation is best had at initiation. Setting realistic expectations — that some temporary shedding is possible but that regrowth is likely once weight stabilizes — can prevent unnecessary medication abandonment.
What Happens Next
The FDA has not set a public timeline for completing its safety signal evaluation. Formal safety reviews of this type typically result in a labeling update or public communication within months to a year, depending on findings. If the FDA determines the signal is sufficient to warrant a label change, hair loss would be added to the prescribing information for semaglutide and tirzepatide — which would require manufacturers Novo Nordisk and Eli Lilly to update their patient information materials.
MedicalDaily will report on any FDA label changes or new prescribing guidance involving GLP-1 drugs and hair loss.
The Bottom Line
A large, rigorous BMJ study from the University of Pennsylvania confirms that GLP-1 drugs including Ozempic, Wegovy, Mounjaro, and Zepbound are associated with a 37 to 68 percent higher relative risk of clinically recorded hair loss compared with other diabetes medications. The absolute risk remains low — roughly 7 out of 1,000 users per year — and the hair loss observed is predominantly the non-scarring type, meaning regrowth is possible once weight loss stabilizes. The FDA is actively evaluating this as a safety signal. Patients who have experienced shedding should discuss it with their clinician rather than stopping medication on their own.
